News

Plant Services7h
Sanofi invests $20B to expand pharmaceutical manufacturing capacity in the United States
The investment includes a significant boost to research and development and the expansion of partnerships with domestic ...
BioPharma Dive3d
Sanofi to acquire Blueprint for up to $9.5B
The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost ...
Fierce Pharma3d
With Opella proceeds burning a hole in its pocket, Sanofi snaps up Blueprint for $9.1B
With the deal, Sanofi gains Blueprint’s portfolio of rare immunological disease treatments, including systemic mastocytosis ...
pharmaphorum1d
ASCO 25: Sanofi hopes on-body delivery will boost Sarclisa
The new version of Sarclisa stems from a collaboration with Enable Injections, backed financially to the tune of €300 million ...
Chemistry World1d
Sanofi to buy Blueprint Medicines for over $9 billion
As part of a strategy to strengthen its immunology segment through acquisitions, Sanofi has agreed to buy US-based Blueprint ...
The Manila Times10h
Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan
Global Employee Stock Purchase Plan . Paris, June 5, 2025. Sanofi's global employee shareholder plan, Action 2025, opens on June 10, 2025, to around 70,000 em ...
Sanofi finds M&A fix for its multiple itches
The French drugmaker will pay up to $9.5 bln for Blueprint Medicines, whose key product fights skin rashes. It eases CEO Paul ...
Fierce Biotech1d
Vigil's rare brain disease drug flunks phase 2 study, but Sanofi takeover is unaffected
A phase 2 study of Vigil Neuroscience’s iluzanebart has missed its biomarker and efficacy endpoints, prompting the ...